BGI Genomics (华大基因)

Shenzhen, China

BGI Genomics provides a wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. BGI’s mission is to leverage its genomics expertise in order to advance life science research and improve human health for the benefit of mankind. BGI has particular strengths in prenatal screening, hereditary cancer screening, testing for rare disease and in aiding precision medicine research and initiatives. Numerous scientific partners, healthcare providers and pharmaceutical companies have come to rely on BGI’s world leading bio-informatics research and development, large scale computing infrastructure for data output and storage, and proprietary sequencing platforms. BGI is headquartered in Shenzhen, China, with branches and medical laboratories in major cities including Beijing, Tianjin, Wuhan, Shanghai and Guangzhou. BGI also has offices and laboratories located in Europe, North America and the Asia Pacific region. BGI currently operates in more than 100 countries and regions and works with more than 3000 medical institutions and more than 300 hospitals.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out BGI Genomics (华大基因) on @MedStartr Today #GeneticDisorders #RareDiseases #GeneralHealth #PrecisionMedicineDiagnostics #MedMo #MedStartrVentures

https://www.medstartr.ai/s/xccmarNvuhQ

Get Involved in BGI Genomics (华大基因)

Company Info

Founded: 2010
Website: www.bgi.com/

Disease Areas

Genetic Disorders Rare Diseases General Health

Technologies

Next-Generation SequencingGenomicsSequencing TechnologyGenetic Testing

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of BGI Genomics (华大基因)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.